Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Lenvatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Astrazeneca's Triplet Combo Succeeds In Liver Cancer Subgroup
    Astrazeneca's Triplet Combo Succeeds In Liver Cancer Subgroup

    01 Jun 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/asco-astrazenecas-imfinzi-imjudo-duo-shines-earlier-stage-liver-cancer-win

    FIERCE PHARMA
    01 Jun 2026
    Share Share
    Medivir Announces First Patient Enrolled In FLEX-HCC Study
    Medivir Announces First Patient Enrolled In FLEX-HCC Study

    21 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-21/medivir-announces-first-patient-enrolled-in-flex-hcc-study

    PHARMIWEB
    21 May 2026
    Share Share
    Eisai Deepens LENVIMA Evidence Across Indications at ASCO 2026
    Eisai Deepens LENVIMA Evidence Across Indications at ASCO 2026

    20 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eisai-deepens-body-of-clinical-evidence-for-lenvima-lenvatinib-across-established-indications-at-asco-2026-302776712.html

    PR NEWSWIRE
    20 May 2026
    Share Share
    Hope Rises For Rare Gynaecological Clear Cell Cancer
    Hope Rises For Rare Gynaecological Clear Cell Cancer

    24 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7206263

    FIRSTWORD PHARMA
    24 Apr 2026
    Share Share
    Merck’s Welireg Triplet Fails Phase 3 in first-line kidney Cancer
    Merck’s Welireg Triplet Fails Phase 3 in first-line kidney Cancer

    22 Apr 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/merck-litespark-shocker-welireg-triplet-misses-mark-first-line-kidney-cancer

    FIERCE PHARMA
    22 Apr 2026
    Share Share
    Merck's Welireg combos deliver 1-2 punch to kidney cancer
    Merck's Welireg combos deliver 1-2 punch to kidney cancer

    28 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/new-standard-merck-welireg-combos-deliver-one-two-punch-kidney-cancer

    FIERCE PHARMA
    28 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.